Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors
ABSTRACT Background Lung cancer treatment has rapidly advanced, particularly with immune checkpoint inhibitors (ICIs) targeting PD‐1 and PD‐L1. However, there are variable responses, such as immune‐related adverse events. Several factors predicting the prognosis of lung cancer ICI treatment have bee...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70826 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|